Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Non-24-Hour Sleep-Wake Disorder
Interventions
DRUG

tasimelteon

20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension

Trial Locations (22)

10003

New York Eye and Ear Infirmary, New York

15221

Consolidated Clinical trials, Pittsburgh

19118

Center for Sleep Medicine at Chestnut Hill Hospital, Philadelphia

20815

The Center for Sleep and Wake Disorders (Washington, D.C. Metropolitan Area), Chevy Chase

29201

SleepMed, Inc. - Columbia, Columbia

30342

Sleep Disorders Center Of Georgia, Atlanta

32174

Neurology Associates of Ormond Beach, Ormond Beach

33185

Kendall South Medical Center, Inc., Miami

33511

PAB Clinical Research Inc., Brandon

43017

Ohio Sleep Medicine Institute (Columbus Metropolitan Area), Dublin

48104

Michigan Head-Pain Neurological Institute, Ann Arbor

60007

Suburban Lung Associates SC (Chicago Metropolitan Area), Elk Grove Village

63017

St. Luke's Sleep Medicine and Research Center (St. Louis Metropolitan Area), Chesterfield

73112

Lynn Health Science Institute, Oklahoma City

77063

Todd J. Swick, M.D., P.A., Houston

80239

Radiant Research - Denver, Denver

85006

Pulmonary Associates, PA, Phoenix

90404

St. Johns Sleep Disorder Center - St. Johns Medical Plaza, Santa Monica

92868

SDS Clinical Trials Inc., Orange

94304

VA Palo Alto Health Care System/PAIRE (San Fransisco Bay Area), Palo Alto

97239

Columbia Research Group Inc., Portland

02115

Brigham and Women's Hospital, Boston

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY